United States - English - NLM (National Library of Medicine)

major pharmaceuticals - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate, usp is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. calcium acetate capsules

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 6.5mmol) effervescent tablets bpc 1968 (actavis uk ltd - potassium bicarbonate; potassium acid tartrate - effervescent tablet - 500mg ; 300mg

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) - concentrate for injection - 100 mg/10ml - active: calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - as rescue therapy to reduce toxicity following high-dose methotrexate therapy. has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions overdosage of methotrexate and in impaired methotrexate elimination reducing the toxicity and circumventing the effect of folic acid antagonists

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) - concentrate for injection - 1000 mg/100ml - active: calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - as rescue therapy to reduce toxicity following high-dose methotrexate therapy. has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions overdosage of methotrexate and in impaired methotrexate elimination reducing the toxicity and circumventing the effect of folic acid antagonists

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) - concentrate for injection - 200 mg/20ml - active: calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - as rescue therapy to reduce toxicity following high-dose methotrexate therapy. has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions overdosage of methotrexate and in impaired methotrexate elimination reducing the toxicity and circumventing the effect of folic acid antagonists

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) - concentrate for injection - 30 mg/3ml - active: calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - as rescue therapy to reduce toxicity following high-dose methotrexate therapy. has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions overdosage of methotrexate and in impaired methotrexate elimination reducing the toxicity and circumventing the effect of folic acid antagonists

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrtae, equivalent to 10 mg/ml folinic acid) - concentrate for injection - 350 mg/35ml - active: calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrtae, equivalent to 10 mg/ml folinic acid) excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - as rescue therapy to reduce toxicity following high-dose methotrexate therapy. has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions overdosage of methotrexate and in impaired methotrexate elimination reducing the toxicity and circumventing the effect of folic acid antagonists

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) - concentrate for injection - 50 mg/5ml - active: calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - as rescue therapy to reduce toxicity following high-dose methotrexate therapy. has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions overdosage of methotrexate and in impaired methotrexate elimination reducing the toxicity and circumventing the effect of folic acid antagonists

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) - concentrate for injection - 500 mg/50ml - active: calcium folinate pentahydrate 10.8 mg/ml (as 12.71 mg/ml of calcium folinate pentahydrate, equivalent to 10 mg/ml folinic acid) excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - as rescue therapy to reduce toxicity following high-dose methotrexate therapy. has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions overdosage of methotrexate and in impaired methotrexate elimination reducing the toxicity and circumventing the effect of folic acid antagonists

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate capsules are a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). patients with hypercalcemia. pregnancy category c calcium acetate capsules  contains calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [ ]. maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate  treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. see warnings